Effects of Exenatide on excess daytime sleepiness (EDS), wakefulness and driving performance in obese type-2 diabetes patients without sleep apnea – proof of concept study - exenatide on daytime sleepiness

Sherwood Forest Hospitals Foundation Trust0 个研究点开始时间: 2009年7月6日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•Inclusion Criteria
•Type 2 diabetes, on a stable medication regimen
•Excess daytime sleepiness (Epworth score >9)
•HbA1c 7.5-12.0%.
•Age 18-65 years
•BMI 28-40
•Subjects would have undergone a sleep study in the sleep laboratory at the Sherwood Forest Hospitals Foundation Trust and sleep apnoea has been excluded.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Exclusion Criteria
•Patients with congestive heart failure, depression, cancer, central nervous system demyelinating disorders, recurrent or active infection.
•HbA1c <7.5% or >12%)
•Age <18 or >65 years
•BMI <28 or >40
•Patients who could not tolerate exenatide therapy
•Presence of obstructive sleep apnoea

发起方

Sherwood Forest Hospitals Foundation Trust